-
Mashup Score: 2
During an OncLive Peer Exchange, a panel of expert clinicians in CRC discussed studies seeking to further define the role of MRD testing in CRC.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
What’s a typical vacation activity for doctors? Work. A new study finds that most physicians do work on a typical day off. In this essay, a family doctor considers why that is and why it matters.
Source: www.npr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
What’s a typical vacation activity for doctors? Work. A new study finds that most physicians do work on a typical day off. In this essay, a family doctor considers why that is and why it matters.
Source: www.npr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
What’s a typical vacation activity for doctors? Work. A new study finds that most physicians do work on a typical day off. In this essay, a family doctor considers why that is and why it matters.
Source: www.npr.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16
RAHWAY, N.J., May 01, 2024–Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
Source: finance.yahoo.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that a late-breaking abstract with preliminary findings from the Phase 2 investigator-sponso
Source: finance.yahoo.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer - 3 month(s) ago
AbstractPurpose:. Pancreatic ductal adenocarcinoma (PDAC) trials have evaluated CTLA-4 and/or PD-(L)1 blockade in patients with advanced disease in which bulky tumor burden and limited time to develop antitumor T cells may have contributed to poor clinical efficacy. Here, we evaluated peripheral blood and tumor T cells from patients with PDAC receiving neoadjuvant chemoradiation plus anti–PD-1 (pembrolizumab) versus chemoradiation alone. We analyzed whether PD-1 blockade successfully reactivated T cells in the blood and/or tumor to determine whether lack of clinical benefit could be explained by lack of reactivated T cells versus other factors.Experimental Design:. We used single-cell transcriptional profiling and TCR clonotype tracking to identify TCR clonotypes from blood that match clonotypes in the tumor.Results:. PD-1 blockade increases the flux of TCR clonotypes entering cell cycle and induces an IFNγ signature like that seen in patients with other GI malignancies who respond to
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM - 5 month(s) ago
Original Article from The New England Journal of Medicine — Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Source: www.nejm.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 52Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer - 6 month(s) ago
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer − FRUZAQLA Plus Best Supportive Care Demonstrated Significant Improvements in Overall Survival, with Corresponding Improvements in Progression Free Survival, Versus Placebo Plus Best Supportive Care in Two Phase 3 Clinical Trials Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for
Source: www.morningstar.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer - 6 month(s) ago
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer − FRUZAQLA Plus Best Supportive Care Demonstrated Significant Improvements in Overall Survival, with Corresponding Improvements in Progression Free Survival, Versus Placebo Plus Best Supportive Care in Two Phase 3 Clinical Trials Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for
Source: www.morningstar.comCategories: General Medicine News, Hem/OncsTweet
RT @OncLive: Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy @benweinbergmd @marshalj23 #crcsm https://t.co/gDRU48b707